Restaurant Brands International Inc. Common Shares vs Viatris Inc — how do they compare? Restaurant Brands International Inc. Common Shares trades at $70.95 (market cap $24.56B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Restaurant Brands International Inc. Common Shares is the larger of the two by market cap, and Restaurant Brands International Inc. Common Shares pays the higher dividend (3.68%). Which is the better fit depends on your goals — on Pluang, investors hold Restaurant Brands International Inc. Common Shares for 1 Days and Viatris Inc for 57 Days on average.
| QSR | VTRS | |
|---|---|---|
Market Cap | $24.56B | $20.03B |
Volume | 3,480,368 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $81.67 | $18.27 |
52-Week Low | $65.69 | $9.74 |
Typical Hold Time | 1 Days | 57 Days |
Enterprise Value | $39.17B | $32.15B |
Dividend Yield | 3.68% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Restaurant Brands International owns and franchises quick-service restaurant brands, including Burger King, Tim Hortons, Popeyes, and Firehouse Subs.
Read more on QSR →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →